Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread?

Pharmacoeconomics. 2017 Nov;35(11):1111-1112. doi: 10.1007/s40273-017-0561-x.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Decision Making*
  • Models, Economic*
  • Uncertainty